Real-World Studies
Cohort study benchmarks outcomes in advanced KRAS G12C-mutant NSCLC
Sheffield et alCancers
In advanced non-small-cell lung cancer (NSCLC), KRAS G12C mutations occur in approximately 13% of cases. This retrospective observational study assessed real-world treatment patterns and clinical outcomes using two nationwide US databases: an electronic health records (EHR) database (n = 1,227) and a clinico-genomic database (CGDB, n = 447) linking EHR entries to comprehensive genomic profiling data for patients initiating first-line therapy between and .
Across the overall EHR cohort, median overall survival (OS) for patients with KRAS G12C-mutant advanced NSCLC was 17.0 months (95% CI: 15.2–18.9). The most common first-line systemic regimen was platinum-based chemotherapy combined with pembrolizumab (46%), followed by pembrolizumab monotherapy (20%). A critical therapeutic attrition point was observed in clinical practice, as fewer than 40% of patients advanced to receive second-line therapy.
Subgroup outcomes varied by treatment selection and biomarker status: • Chemoimmunotherapy: Patients treated with first-line platinum-based chemotherapy plus pembrolizumab demonstrated a median real-world progression-free survival (rwPFS) of 5.3 months (95% CI: 4.5–7.3) and a median OS of 12.8 months (95% CI: 11.1–17.3) in the CGDB, with a median OS of 15.6 months (95% CI: 12.5–18.6) in the EHR database. • Single-Agent Immunotherapy: Among patients with high PD-L1 expression (≥50%) receiving first-line pembrolizumab monotherapy, median rwPFS was 4.6 months (95% CI: 3.0–15.6) and median OS was 20.4 months (95% CI: 10.3–38.5) in the CGDB; median OS reached 22.1 months (95% CI: 18.7–30.7) in the EHR database.
Multivariable analyses demonstrated that PD-L1 expression <1%, the presence of baseline brain metastases, STK11 co-mutations, and poor baseline performance status were each significantly associated with inferior overall survival. These real-world benchmarks establish current standards of care outcomes and highlight an ongoing unmet need for optimized frontline therapeutic regimens in KRAS G12C-mutated NSCLC.
Key Takeaways
- First-line platinum-based chemotherapy plus pembrolizumab yielded a median real-world progression-free survival of 5.3 months (95% CI: 4.5–7.3) and a median overall survival of 12.8 months (95% CI: 11.1–17.3) in the clinico-genomic cohort, and 15.6 months (95% CI: 12.5–18.6) in the electronic health record cohort.
- In patients with PD-L1 expression ≥50% receiving first-line pembrolizumab monotherapy, median real-world progression-free survival was 4.6 months (95% CI: 3.0–15.6), with median overall survival of 20.4 months (95% CI: 10.3–38.5) in the clinico-genomic cohort and 22.1 months (95% CI: 18.7–30.7) in the electronic health record cohort.
- Significant clinical predictors of shorter overall survival included PD-L1 expression <1%, brain metastases, STK11 co-mutations, and poor performance status, with fewer than 40% of patients successfully receiving second-line therapy.
Read the original sourceCancers
